Company Overview and News
The 35 largest U.S. banks are poised to put more money toward dividends, share buybacks and business investments, after clearing the first stage of an annual regulatory stress test on Thursday, showing they have enough capital to withstand an extreme recession.
C.WSA COF.WS GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA GLSSP UGLD UBS.PRDCL MS JBK DSLV COF-P CSSLF PNC.PRP TFG PNC.PRQ PNCFO GS.PRJ GS.PRI PNC.WS MS.PRI GS.PRD MS.PRK CGBBW GS.PRC PNC GS.PRN GS.PRK COF.PRG WFCNP COF.PRH DB DGLD WFC.PRL COF.PRP WFC.PRJ CS COF-D WFC.PRT GS COF-C C.WS.B COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO UBS WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY COF.PRC WFC.PRX COF.PRD WFC.PRW WFC.PRV COF.PRF C.PRS WFC WFC.WS C.PRL C VIIX GSC GS.PRICL C.PRJ VIIZ C.PRK COF C.PRG GSJ C.PRC CSGKF C.PRPCL PNUCL ZIV USLV TVIX GJS ULSGF XIV
It has become harder and harder to find good investment ideas that trade at reasonable multiples, have some decent upside potential, and also pay dividends. One sector that was on fire for most of last year, has been beaten down hard recently despite a plethora of positives in the group. The financials are offering growth investors the best entry points in years, and could be a leading sector the rest of 2018.
WFCNP C.WSA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL PNC.PRP C.PRJ PNC.PRQ C.PRK PNCFO C.PRG C.PRC PNC.WS JPM C.PRPCL CGBBW PNC PNUCL
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DGLD GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA CS GS GLSSP UGLD STI-A STI.PRE MS JBK STI.WS.B STI.WS.A DSLV VIIX GSC GS.PRICL CSSLF PNC.PRP VIIZ TFG PNC.PRQ PNCFO GSJ GS.PRJ GS.PRI CSGKF PNC.WS STI MS.PRI GS.PRD MS.PRK GS.PRC PNC PNUCL ZIV USLV TVIX GS.PRN GJS GS.PRK XIV
Global stock markets rebounded yesterday after political crises in Italy and Spain sent stocks into a tailspin. Unfortunately, for investors things could get worse from here.
PNC.WS PNC.PRP PNC PNC.PRQ PNUCL PNCFO
On May 28, we issued an updated research report on The PNC Financial Services Group (PNC - Free Report) . The company’s cost-containment efforts to drive operational efficiency along with steady loan and deposit growth indicate its upside potential. However, lack of loan diversification remains a concern.
HRL CMA.WS PNC.WS NTRS CMA PNC.PRP NTRSP PNC PNC.PRQ PNUCL PNCFO CMPWW
The days of increased regulatory scrutiny are over for U.S. financial stocks. The Congress approved a plan on May 22 to scale down stringent banking regulations or the Dodd-Franck act undertaken in the height of the 2008 financial crisis.
CBSH STT.PRC STT.PRE TCBI STT.PRD STT.PRG GDOT KRE STT SBNY SBNYW CBSHP PNC.PRP PNC.PRQ PNCFO TCBIL PACW UTX FFIN CBCB TCBIW PNC.WS TCBIP PNC PNUCL EWBC KBE
Main Street banks are feeling squeezed by competition from new rivals: nonbanks like hedge funds and private-equity firms that are elbowing into business loans.
RF.PRB STI.WS.B RF.PRA STI.WS.A PNC.PRP PNC.PRQ RF PNCFO FITBI PNC.WS STI STI-A PNC PNUCL STI.PRE FITB
Village Bank & Trust Financial Corp. (NASDAQ:VBFC) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 713,523 shares. Largest shareholders include Lehman Kenneth R, Pnc Financial Services Group, Inc., Banc Funds Co Llc, Minerva Advisors LLC, Geode Capital Management, Llc, River Oaks Capital LLC, UBS Group AG, Deutsche Bank Ag\, Morgan Stanley, and Bessemer Group Inc.
DB PNC.PRP PNC.PRQ MS.PRE CEI PNCFO MS.PRF MS.PRG ABEO MS.PRA PNC.WS MS.PRI UBS MS.PRK PNC PNUCL UBS.PRDCL VBFC MS ABEOW ULSGF
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET